SEARCH:   Advanced

Blood, 15 June 2005, Vol. 105, No. 12, pp. 4878-4884. Prepublished online as a Blood First Edition Paper on February 24, 2005; DOI 10.1182/blood-2004-12-4825. This Article Full Text Full Text (PDF) Supplemental Table All Versions of this Article: 2004-12-4825v1 105/12/4878    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hsu, K. C. Articles by Dupont, B. Search for Related Content PubMed PubMed Citation Articles by Hsu, K. C. Articles by Dupont, B. Related Collections Transplantation Clinical Trials and Observations Immunobiology Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes Katharine C. Hsu, Carolyn A. Keever-Taylor, Andrew Wilton, Clara Pinto, Glenn Heller, Knarik Arkun, Richard J. O'Reilly, Mary M. Horowitz, and Bo Dupont From the Allogeneic Marrow Transplantation Service and the Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York; the Immunology Program, Sloan-Kettering Institute for Cancer Research, New York, NY; and the Bone Marrow Transplant Program, Froedtert Memorial Lutheran Hospital, Medical College of Wisconsin, Milwaukee. Inhibitory killer immunoglobulin (Ig)-like receptors (KIRs) recognize HLA-C and -B epitopes on target cells, thereby regulating natural killer (NK) cell activity. In 178 patients receiving T-cell-depleted HLA-identical sibling transplants for acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndrome (MDS), analysis of donor KIR genotype with HLA genotype demonstrated that 62.9% of the patients lacked an HLA ligand for donor-inhibitory KIR. Lack of HLA ligand for donor-inhibitory KIR (missing KIR ligand) had no effect on disease-free survival (DFS), overall survival (OS), or relapse in patients receiving transplants for CML and ALL. In patients with AML and MDS, however, there was a significant missing KIR ligand effect on DFS (P = .014; hazard ratio [HR], 0.53; 95% confidence interval [95% CI], 0.28-0.88) and OS (P = .03; HR, 0.53; 95% CI, 0.3-0.93). Incidence of relapse was also lower in patients with AML and MDS who lacked the HLA ligand for donor-inhibitory KIR (P = .04; HR, 0.41; 95% CI, 0.18-0.97). AML and MDS patients lacking 2 HLA ligands for donor-inhibitory KIR had the highest DFS (P = .002) and OS (P = .003). There was no significant contribution of donor-activating KIR to transplantation outcome in these patients. These data indicate that the absence of class I ligand in the recipient for donor-inhibitory KIR can be a prognostic factor for transplantation outcome in HLA-identical sibling transplantation and that the lack of HLA-C or -B ligands for donor-inhibitory KIR can contribute to improved outcomes for patients with AML and MDS. (Blood. 2005;105:4878-4884) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. Iizuka, A. A. Scalzo, H. Xian, and W. M. Yokoyama Regulation of the NK Cell Alloreactivity to Bone Marrow Cells by the Combination of the Host NK Gene Complex and MHC Haplotypes J. Immunol., March 1, 2008; 180(5): 3260 - 3267. [Abstract] [Full Text] [PDF] S. Kim, J. B. Sunwoo, L. Yang, T. Choi, Y.-J. Song, A. R. French, A. Vlahiotis, J. F. Piccirillo, M. Cella, M. Colonna, et al. HLA alleles determine differences in human natural killer cell responsiveness and potency PNAS, February 26, 2008; 105(8): 3053 - 3058. [Abstract] [Full Text] [PDF] J. Yu, G. Heller, J. Chewning, S. Kim, W. M. Yokoyama, and K. C. Hsu Hierarchy of the Human Natural Killer Cell Response Is Determined by Class and Quantity of Inhibitory Receptors for Self-HLA-B and HLA-C Ligands J. Immunol., November 1, 2007; 179(9): 5977 - 5989. [Abstract] [Full Text] [PDF] J. H. Chewning, C. N. Gudme, K. C. Hsu, A. Selvakumar, and B. Dupont KIR2DS1-Positive NK Cells Mediate Alloresponse against the C2 HLA-KIR Ligand Group In Vitro J. Immunol., July 15, 2007; 179(2): 854 - 868. [Abstract] [Full Text] [PDF] L. Ruggeri, A. Mancusi, M. Capanni, E. Urbani, A. Carotti, T. Aloisi, M. Stern, D. Pende, K. Perruccio, E. Burchielli, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood, July 1, 2007; 110(1): 433 - 440. [Abstract] [Full Text] [PDF] J. S. Miller, S. Cooley, P. Parham, S. S. Farag, M. R. Verneris, K. L. McQueen, L. A. Guethlein, E. A. Trachtenberg, M. Haagenson, M. M. Horowitz, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT Blood, June 1, 2007; 109(11): 5058 - 5061. [Abstract] [Full Text] [PDF] A. Lundqvist, J. Philip McCoy, L. Samsel, and R. Childs Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors Blood, April 15, 2007; 109(8): 3603 - 3606. [Abstract] [Full Text] [PDF] J. C. Fischer, H. Ottinger, S. Ferencik, M. Sribar, M. Punzel, D. W. Beelen, M. A. Schwan, H. Grosse-Wilde, P. Wernet, and M. Uhrberg Relevance of C1 and C2 Epitopes for Hemopoietic Stem Cell Transplantation: Role for Sequential Acquisition of HLA-C-Specific Inhibitory Killer Ig-Like Receptor J. Immunol., March 15, 2007; 178(6): 3918 - 3923. [Abstract] [Full Text] [PDF] A. Mullally and J. Ritz Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation Blood, February 15, 2007; 109(4): 1355 - 1362. [Abstract] [Full Text] [PDF] J. H. Park, A. J. Yee, T. R. Spitzer, S. L. Saidman, D. T. Ting, A. Pannone, J. Reid, S. McAfee, and B. R. Dey KIR Ligand Incompatibility in HLA-Identical Sibling Nonmyeloablative Hematopoietic Stem Cell Transplantation for Hematologic Malignancies. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 5371 - 5371. [Abstract] [PDF] C. J. VandenBussche, S. Dakshanamurthy, P. E. Posch, and C. K. Hurley A Single Polymorphism Disrupts the Killer Ig-Like Receptor 2DL2/2DL3 D1 Domain J. Immunol., October 15, 2006; 177(8): 5347 - 5357. [Abstract] [Full Text] [PDF] A. P. Williams, A. R. Bateman, and S. I. Khakoo HANGING IN THE BALANCE: KIR and Their Role in Disease Mol. Interv., August 1, 2005; 5(4): 226 - 240. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020